19 Nov 2019 07:00
19 November 2019
Collagen Solutions plc
("Collagen Solutions" or the "Company")
Investor results presentation
Collagen Solutions Plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces it will hold an investor results briefing on Tuesday, 3 December 2019.
The Company will announce its interim results for the six months ending 30 September 2019 on 3 December 2019 and will provide an update to investors that day. A briefing will take place at the Brand Exchange, 3 Birchin Lane, London EC3V 9BW at 4.30pm for a 4.45pm start.
Jamal Rushdy, CEO and Hilary Spence, CFO will give an overview of the results and the Company's future plans for growth. This will be followed by drinks and a chance to network.
To register, please call 020 7933 8780 or email collagen@walbrookpr.com.
Collagen Solutions Plc |
| |
Jamal Rushdy, CEO | Via Walbrook | |
Hilary Spence, CFO |
| |
|
| |
Walbrook PR Ltd | Tel: 020 7933 8780 or collagen@walbrookpr.com | |
Anna Dunphy | Mob: 07876 741 001 | |
About Collagen Solutions:
Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, tissue engineering, and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic®. The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.
For more information go to: www.collagensolutions.com